
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.

Pipeline· June 3, 2026 · 9 min read
By Ran Chen#PDUFA Date#FDA Approval#Immunology

Pricing & Access· June 3, 2026 · 15 min read
GLP-1 insurance coverage 2026: major payer guide
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization

Pipeline· June 3, 2026 · 10 min read
NASP PDUFA preview: anti-drug antibody strategy for uncontrolled gout
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Approvals· June 2, 2026 · 9 min read
Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis

Pipeline· June 1, 2026 · 10 min read
Enhertu early-stage breast cancer: neoadjuvant and adjuvant PA workflow
By Ran Chen#Oncology#FDA Approval#Prior Authorization

Pricing & Access· May 31, 2026 · 15 min read
Biomarker documentation mismatch in oncology prior authorization
By Ran Chen#Oncology#Prior Authorization#Payer Policy

Pricing & Access· May 31, 2026 · 12 min read
Companion diagnostic denial before oncology drug prior authorization

Pricing & Access· May 31, 2026 · 13 min read
Electronic prior authorization readiness for specialty drugs in 2027
By Ran Chen#Prior Authorization#CMS#Specialty Drugs

Pricing & Access· May 31, 2026 · 13 min read
FHIR prior authorization fields that cause specialty-drug denials
By Ran Chen#Prior Authorization#CMS#Specialty Drugs

Pricing & Access· May 31, 2026 · 12 min read
GLP-1 appeal evidence after cardiometabolic comorbidity denial
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs